Beam Therapeutics (BEAM) Research & Development (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Research & Development data on file, last reported at $104.5 million in Q1 2026.

• On a quarterly basis, Research & Development rose 5.78% year-over-year to $104.5 million in Q1 2026; TTM through Mar 2026 was $415.3 million, a 8.85% increase from a year earlier, with the FY2025 full-year figure at $409.6 million, up 11.44% from the prior year.
• Research & Development for Q1 2026 stood at $104.5 million, up from $99.3 million in the prior quarter.
• Over the last five years, Research & Development for BEAM reached as high as $140.1 million in Q4 2023 and fell as low as $65.4 million in Q1 2022.
• Historically, Research & Development has averaged $95.9 million across 5 years, with a median of $98.8 million in 2025.
• On a YoY basis, Research & Development climbed as much as 63.58% in 2022 and fell as far as 65.59% in 2022.
• Year by year, Research & Development stood at $86.3 million in 2022, then surged by 62.24% to $140.1 million in 2023, then fell by 27.58% to $101.4 million in 2024, then dropped by 2.14% to $99.3 million in 2025, then increased by 5.29% to $104.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $104.5 million in Q1 2026, $99.3 million in Q4 2025, and $109.8 million in Q3 2025.